Current treatments Currently, there are no treatments prescribed for<unk> . All treatments administered are in response to secondary pathologies that develop as a consequence of the<unk> . Because white matter injury in the<unk>  region can result in a variety of deficits, neurologists must closely monitor infants diagnosed with<unk>  in order to determine the severity and extent of their conditions. Patients are typically treated with an individualized treatment. It is crucial for doctors to observe and maintain organ function: visceral organ failure can potentially occur in untreated patients. Additionally, motor deficits and increased muscle tone are often treated with individualized physical and occupational therapy treatments. Treatment challenges The fetal and neonatal brain is a rapidly changing, developing structure. Because neural structures are still developing and connections are still being formed at birth, many medications that are successful for treatment and protection in the adult central nervous system (CNS) are ineffective in infants. Moreover, some adult treatments have actually been shown to be toxic to developing brains. Future treatments Although no treatments have been approved for use in human<unk>  patients, a significant amount of research is occurring in developing treatments for protection of the nervous system. Researchers have begun to examine the potential of synthetic neuroprotection to minimize the amount of lesioning in patients exposed to ischemic conditions.
Periventricular leukomalacia
Hemicrania continua
Gray matter heterotopia
Schizencephaly
Dandy–Walker malformation
Intracranial dolichoectasias
Intraventricular hemorrhage
Neonatal encephalopathy